Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single-center retrospective study of patients with unresectable HCC treated with triple combination therapy comprising angiogenesis inhibitors (oral apatinib, lenvatinib, or sorafenib), anti-programmed cell death 1 antibodies (iv camrelizumab or sintilimab), and hepatic arterial infusion chemotherapy (FOLFOX).

Next Previous
X
Search
Trial Profile

Single-center retrospective study of patients with unresectable HCC treated with triple combination therapy comprising angiogenesis inhibitors (oral apatinib, lenvatinib, or sorafenib), anti-programmed cell death 1 antibodies (iv camrelizumab or sintilimab), and hepatic arterial infusion chemotherapy (FOLFOX).

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Lenvatinib (Primary) ; Oxaliplatin (Primary) ; Rivoceranib (Primary) ; Sintilimab (Primary) ; Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 22 Jul 2021 New trial record
    • 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top